Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2023-08-11 Interim / Quarterly Rep…
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Financial Statements For the quarterly period ended June 30, 2023
Interim / Quarterly Report Classification · 100% confidence The document is explicitly titled 'FORM 10-Q' and identified as a 'QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934'. It contains comprehensive financial statements, management's discussion and analysis, and other required disclosures for the quarterly period ended June 30, 2023. This fits the definition of an Interim/Quarterly Report (IR). Q2 2023
2023-08-11 English
Financial Statements For the quarterly period ended June 30, 2023
Report Publication Announcement Classification · 100% confidence The document is a short notification (under 2,000 characters) from Oramed Pharmaceuticals Inc. submitted to the Israel Securities Authority. It explicitly states 'Attached hereto is a report on Form 10-Q - Q2 2023' and provides a filename for the attachment. Per the 'MENU VS MEAL' rule, this is an announcement of a report rather than the report itself, and therefore qualifies as a Report Publication Announcement (RPA). H1 2023
2023-08-11 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2023
2023-08-10 English
Form 8-K-STOCK PURCHASE AGREEMENT, Replacement DIP Loan Agreement
Regulatory Filings Classification · 98% confidence The document explicitly states it is a "FORM 8-K" and a "CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934". Form 8-K filings report significant, unscheduled material events. The content details the entry into a "Stock Purchase Agreement" (Item 1.01) and a "Replacement DIP Loan Agreement" related to bankruptcy proceedings. Since Form 8-K is a specific SEC filing type that reports material corporate events and does not align with the provided definitions (like 10-K for annual reports, ER for earnings releases, or CAP for general financing updates), the most appropriate classification from the provided list is the general regulatory fallback category, "Regulatory Filings" (RNS), as 8-K is a standard regulatory disclosure document not covered by the more specific options.
2023-08-09 English
Form 8-K-STOCK PURCHASE AGREEMENT, Replacement DIP Loan Agreement
Regulatory Filings Classification · 95% confidence The document explicitly mentions being filed under 'Other Report or Announcement' referencing 'Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000' and states that 'Attached hereto is a report on *Form 8-K*'. A Form 8-K is an 'Current Report' used in the US to announce major events that shareholders should know about. Since the document itself is an announcement referencing an attached 8-K, and it doesn't fit the specific definitions for ER (Earnings Release), MRQ (Major Shareholding), or DIV (Dividend), it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous, immediate regulatory disclosure, especially given the short length and the nature of announcing an attached filing.
2023-08-09 English
CURRENT REPORT
Regulatory Filings
2023-08-09 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.